Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Shares Cross Above 200-Day Moving Average – What’s Next?

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) shares passed above its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $55.47 and traded as high as $67.11. Global X Genomics & Biotechnology ETF shares last traded at $64.31, with a volume of 34,041 shares changing hands.

Global X Genomics & Biotechnology ETF Stock Down 4.0%

The company’s 50-day moving average is $65.45 and its 200-day moving average is $55.47. The stock has a market capitalization of $102.90 million, a price-to-earnings ratio of -27.48 and a beta of 1.17.

Institutional Trading of Global X Genomics & Biotechnology ETF

Hedge funds and other institutional investors have recently made changes to their positions in the company. Polaris Financial Partners acquired a new position in Global X Genomics & Biotechnology ETF in the third quarter valued at approximately $1,067,000. Bank of America Corp DE increased its stake in Global X Genomics & Biotechnology ETF by 67.8% during the first quarter. Bank of America Corp DE now owns 119,795 shares of the company’s stock worth $5,240,000 after acquiring an additional 48,394 shares during the last quarter. Farther Finance Advisors LLC acquired a new stake in Global X Genomics & Biotechnology ETF during the third quarter worth $257,000. Halbert Hargrove Global Advisors LLC acquired a new stake in Global X Genomics & Biotechnology ETF during the third quarter worth $77,000. Finally, Wealth Management Partners LLC purchased a new stake in Global X Genomics & Biotechnology ETF in the first quarter valued at $244,000. Institutional investors and hedge funds own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.